Presbyopia is caused by a stiffening in the lens of the eye that develops in people after the age of 40, and affects an estimated 128 million people in the US. AbbVie is recommending Vuity ...

To assess visual performance and overall satisfaction with EDOF CLs, Kamiya and colleagues conducted a prospective study in 42 eyes of 21 subjects with presbyopia. They assessed visual acuity at ...

As we age, many changes occur within our bodies, including a gradual decline in our reading vision, known as presbyopia. This natural process, which typically begins in our 40s, can lead to ...

Alcon Inc. ALC recently introduced the Clareon PanOptix Pro intraocular lens (IOL) for cataract patients in the United States. PanOptix Pro leverages proprietary ENLIGHTEN NXT Optical technology to ...

LENZ Therapeutics (formerly Presbyopia Therapies) is working on eyedrops containing aceclidine – thought to act like pilocarpine as a miotic agent, reducing eye pressure – showed improvements ...

LENZ Therapeutics, Inc.'s LNZ100 eye drops show strong phase 3 results for presbyopia, outperforming competitors. Click here ...

Phakic IOL technologies have undergone substantial improvements in recent years, with progressive upgrades in design and material and more accurate sizing strategies.At the ESCRS winter meeting, Erik ...

Alcon ALC recently announced that its Clareon Vivity intraocular lens (IOL), featuring extended depth of focus (EDOF) ...

New Drug Application (NDA) for LNZ100 for treatment of presbyopia on track for PDUFA target action date of August 8, 2025 Upon FDA approval, commercial launch activities to commence immediately with ...